TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26084276
Drug: Miglustat 100
Normalized name: miglustat 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat 100 mg t.i.d. + S. boulardii 500 mg b.i.d.
Study: 26084276
Drug: Miglustat 100
Normalized name: miglustat 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat 100 mg t.i.d. + placebo
Study: 23351522
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Olanzapine
Study: 30361250
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Placebo
Study: 18259972
Drug: Arformoterol 15
Normalized name: arformoterol 15 mcg/2 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol 15 micro g BID
Study: 18259972
Drug: Arformoterol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol 25 micro g BID
Study: 18259972
Drug: Arformoterol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol 50 micro g QD
Study: 18259972
Drug: Salmeterol 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 42 micro g BID
Study: 9165581
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg estramustine phosphate (EMP) per day
Study: 9165581
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg diethylstilbestrol (DES) per day
Study: 9835726
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (NSAIDs)
Study: 2903827
Drug: Oral dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of xamoterol
Study: 2903827
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pharmacokinetics in cardiac failure patients vs young healthy male volunteers
Study: 27237709
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol 30 mg b.d. for 52 weeks
Study: 23276888
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) with oral calcium and vitamin D supplementation
Study: 17655781
Drug: Physostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (30 µg kg-1)
Study: 15178717
Drug: 25,000 IU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU/mL r‐UK
Study: 15178717
Drug: 15,000 IU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15,000 IU/mL r‐UK
Study: 15178717
Drug: 5,000 IU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU/mL r‐UK
Study: 8450459
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg/70 kg)
Study: 8450459
Drug: Triazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.75 mg/70 kg)
Study: 8450459
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg/70 kg)
Study: 23303874
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily)
Study: 8243878
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (65 micrograms/kg)
Study: 2938849
Drug: Selective inhibitor
Normalized name: EGFR MUTANT-SELECTIVE INHIBITOR BLU-945
DrugBank: Tigozertinib (DB19239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective inhibitor of thromboxane synthase, imidazo (1,5‐2) pyridine‐5‐hexanoic acid, administered under randomized, double‐blind, controlled conditions.
Study: 2938849
Drug: Aspirin (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (as a control for platelet cyclooxygenase inhibition)
Study: 2938849
Drug: Long-term dosing
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dosing with the synthetic inhibitor of thromboxane synthase
Study: 2938849
Drug: Thromboxane synthase
Normalized name: Thromboxane synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboxane synthase inhibitor
Study: 25947202
Drug: Peer mentoring
Normalized name: IRRIGATOR,GREER MENTOR #6004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer mentoring intervention to reduce teenage pregnancy; details on dosage and duration not available.
Study: 23911273
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose-adjustment (CDA) according to PR monitoring
Study: 21996146
Drug: Prasugrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel therapy
Study: 22235508
Drug: Biguanide (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biguanide (metformin 500 mg three times daily)
Study: 22235508
Drug: Statin (simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (simvastatin 20 mg daily)
Study: 22235508
Drug: Biguanide (metformin)
Normalized name: biguanide
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biguanide (metformin)
Study: 16217850
Drug: Frequent assessment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent assessment (16 postbaseline visits, twice-weekly for 8 weeks)
Study: 15271855
Drug: 50% decreased
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% decreased vegetable intake (75 g/day) for 2 weeks
Study: 15271855
Drug: Doubled vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubled vegetable intake (300 g/day) for 2 weeks
Study: 11011807
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) tinzaparin, dosage regimen not specified
Study: 9369265
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 (300 mg)
Study: 23092692
Drug: Multispecies combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies combination containing Lactobacillus rhamnosus GG
Study: 26541658
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg q8 h orally for 7 days)
Study: 21964491
Drug: G‐CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (300 μg)
Study: 21478189
Drug: Infliximab 6
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 6 mg/kg
Study: 12010361
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (3TC) treatment in the presence of M184V mutation
Study: 24621971
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3 g/day
Study: 7027432
Drug: Aspirin 3
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3 g
Study: 28229278
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified doogh (FD; containing 170 mg calcium and 500 IU/250 mL)
Study: 26004966
Drug: Prilocaine in
Normalized name: prilocaine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine in tumescent solution
Study: 21641345
Drug: SLV320 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV320 1.25 mg
Study: 21641345
Drug: SLV320 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV320 3.75 mg
Study: 21641345
Drug: SLV320 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV320 7.5 mg
Study: 19919976
Drug: SLV320 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV320 15 mg
Study: 10930154
Drug: Antenatal monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal monotherapy predominantly with zidovudine (ZDV)
Study: 26663387
Drug: LCZ696 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (400 mg, n = 21)
Study: 29304421
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40IU)
Study: 24882155
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (20IU)
Study: 1951158
Drug: 1.1 g
Normalized name: Giazo 1.1 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 g carbohydrate/kg body mass (LC)
Study: 1951158
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g carbohydrate/kg body mass (HC)
Study: 29860341
Drug: Intensive l-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive l-asparaginase therapy in the intermediate risk group
Study: 21718265
Drug: Twice-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly resistance training
Study: 23308123
Drug: Twice-weekly balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly balance and tone training
Study: 15923407
Drug: Dual combinations
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combinations of HIV-1 reverse transcriptase inhibitors
Study: 15923407
Drug: Triple combinations
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combinations of HIV-1 reverse transcriptase inhibitors
Study: 15694110
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo
Study: 6303264
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (0.3 to 4 mg/kg)
Study: 31425585
Drug: CSSO during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSSO during creep-feeding (CF) at 80 g/d per steer
Study: 31425585
Drug: CSSO during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSSO during preconditioning (PC) at 150 g/d per steer
Study: 12560628
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 0.125 percent bupivocaine and morphine after combined general‐epidural anesthesia
Study: 8565975
Drug: Warm underwater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm underwater water-jet massage (3 times, 20 min each) during treatment week
Study: 2168152
Drug: Drug-resistant mutant
Normalized name: Streptococcus mutans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant mutant [SR2‐410(r)]
Study: 2168152
Drug: Drug-dependent mutant
Normalized name: Streptococcus mutans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-dependent mutant [SR2‐410(d)]
Study: 14616929
Drug: L‐NG methylarginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NG methylarginine hydrochloride (L‐NMMA:546C88) 6 mg/kg
Study: 30041183
Drug: LPNYL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPNYL treatment (energy density of 45 J/cm2, pulse width of 35 ms, spot size of 4 mm, frequency of 1 Hz, 6 treatments with 1-week intervals)
Study: 30041183
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (drug group)
Study: 22420596
Drug: Allopurinol augmentation
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol augmentation
Study: 18779477
Drug: Implanted eyes
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implanted eyes (both doses)
Study: 11502317
Drug: Sulfadoxine/pyrimethamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine) plus placebo
Study: 11502317
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg/kg) plus placebo
Study: 8489974
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml plain bupivacaine 0.5% injected at a rate of 0.05 ml/sec
Study: 27376184
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus corticosteroid (CS) injection
Study: 20828359
Drug: 5 cm²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 cm² rivastigmine patch (4.5 mg/24 h)
Study: 20828359
Drug: 15 cm²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 cm² rivastigmine patch (13.3 mg/24 h)
Study: 17680819
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol
Study: 10870801
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin (daily for 1 week)
Study: 10870801
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aspirin (daily for 1 week)
Study: 26962518
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Depo‐Medrol injection plus full time neutral wrist splint (Group B)
Study: 20663187
Drug: Dextrose 150
Normalized name: caffeine/dextrose 150 mg-300 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 150 g (600 kcals)
Study: 7944997
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg tid for 6 months)
Study: 2905252
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 150 mg at bedtime
Study: 2908751
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 150 mg post cenam nocte
Study: 31941792
Drug: Double-injection costoclavicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection costoclavicular block
Study: 31941792
Drug: Single-injection costoclavicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection costoclavicular block
Study: 23737646
Drug: Immunotherapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (not explicitly detailed in the abstract)
Study: 22921287
Drug: Mirodenafil 100
Normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirodenafil 100 mg
Study: 19068007
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Behavioral Treatment (IT)
Study: 16912128
Drug: sitagliptin 25
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 25 mg
Study: 16912128
Drug: sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 200 mg
Study: 12388137
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oxymetholone daily for 12 weeks
Study: 21854580
Drug: Oral topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral topiramate (n = 36) as an add-on to cognitive behavioural therapy (CBT)
Study: 21854580
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) only (controls: n = 3 × 36)
Study: 19250078
Drug: Gold-tip ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold-tip ablation catheter (group G)
Study: 17915468
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of halotherapy (HT) and endobronchial helium‐neon laser irradiation (ELI) with traditional drug therapy (DT) in moderate persistent asthma
Study: 11677365
Drug: NG-mononmethyl-l-arginine (co-infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-l-arginine (co-infused with Ang(1-7))
Study: 3286722
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil 2 mg
Study: 3169109
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil 10 mg
Study: 3286722
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil 20 mg
Study: 3286722
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil 10 mg (exercise challenge)
Study: 30202872
Drug: Standard MDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MDA (annual praziquantel plus 6 monthly single-dose albendazole)
Study: 29043996
Drug: rhBNP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP and dopamine combination treatment
Study: 15948997
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg BIW
Study: 23011358
Drug: Etanercept 10
Normalized name: Etanercept 10 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 10 mg BIW
Study: 19133409
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs supplementation (2.4 g/day for 24 weeks)
Study: 12057618
Drug: HBsAg/AS04 hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg/AS04 hepatitis B vaccine (administered on a 0 and 6 months schedule)
Study: 12057618
Drug: Licensed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed hepatitis B vaccine (Engerix-B, administered on a 0, 1 and 6 months schedule)
Study: 9839765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of donepezil HCl (5 mg) and digoxin (0.25 mg)
Study: 2547709
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg in grapefruit juice)
Study: 899844
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) treatment at doses of 200, 400, or 600 mg per day
Study: 27825272
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg twice daily for five days
Study: 2904116
Drug: Propoxyphene (Darvon),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (Darvon), 100 mg q.i.d.
Study: 2904116
Drug: Acetaminophen (Tylenol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d.
Study: 22777333
Drug: sequential IRIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential IRIS + bevacizumab
Study: 20471302
Drug: Dynamic Contour
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic Contour Tonometry (DCT) with daily disposable hydrogel contact lens in situ
Study: 20471302
Drug: Dynamic Contour
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic Contour Tonometry (DCT) without daily disposable hydrogel contact lens
Study: 17185423
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.2 g DHA and 1.1 g EPA/day)
Study: 15218329
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine (20 mg/kg dry body weight three times weekly after haemodialysis) for 16 weeks
Study: 28281731
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors
Study: 9269694
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg daily
Study: 3132028
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg alprenolol twice daily
Study: 18458040
Drug: One course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Study: 16921009
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management intervention (monthly telephone contact and information/referral services)
Study: 8421165
Drug: Monovalent B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent B (Mono B) followed by bivalent CR influenza A (Bi A) vaccine
Study: 12968395
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (44 micrograms/ml of depigmented, polymerized allergen extract)
Study: 12968395
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (no specific immunotherapy)
Study: 6083597
Drug: 3-hydroxy-3-methylglutaric acid
Normalized name: 3-hydroxy-4-methoxybenzenesulfonic acid
DrugBank: Meglutol (DB04377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hydroxy-3-methylglutaric acid (HMGA) 1 g three times a day orally for 4 weeks
Study: 30880072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3)
Study: 30880072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpelisib and olaparib
Study: 22555869
Drug: i.v. pethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pethidine plus EMLA cream (group A)
Study: 22555869
Drug: i.v. pethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pethidine plus placebo hydrating cream (group B)
Study: 18035190
Drug: GLY+RSG (glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY+RSG (glyburide 10 or 20 mg plus rosiglitazone 8 mg)
Study: 10655977
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg CuSO4
Study: 10699742
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg Cu glycine chelate (CuG)
Study: 10699742
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (7 mg/d)
Study: 9095564
Drug: Two 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 10 mg controlled-release oxycodone tablets
Study: 3101709
Drug: Interferon-gamma (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (50 micrograms, reduced to 20 or 10 micrograms in case of side effects), administered 3 to 7 times per week by subcutaneous route for 2 to 6 weeks.
Study: 16202499
Drug: Clearfil SE
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearfil SE Bond (SE) with gentle air-blowing (g)